Immunomedics, Inc. (IMMU) Says 90 Y-Clivatuzumab Tetraxetan in Combo With Low-Dose Gemcitabine Active
10/23/2013 8:00:28 AM
Immunomedics, Inc. (Nasdaq: IMMU [FREE Stock Trend Analysis]), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that multiple cycles of therapy with the Company's pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90 (^90Y), in combination with low-dose gemcitabine, produced a median overall survival (OS) of more than 5 months in patients with metastatic pancreatic cancer who had received at least 2 prior treatments.
Help employers find you! Check out all the jobs and post your resume.
comments powered by